Genetic Risk Assessment Tool for Prostate Cancer
Prostate cancer can be difficult to assess, especially when trying to understand how aggressive the disease might be. This technology will help doctors detect prostate cancer more precisely by counting copies of a genetic sequence known as line-1.
The Problem
Prostate cancer can be difficult to assess, especially when trying to understand how aggressive the disease might be. One of the markers linked to cancer progression, known as LINE-1, is often overlooked in current genetic tests. Without tools to measure this marker, doctors may not have the full picture needed to make the best treatment decisions. There is a need for better diagnostic tools that can detect these important genetic signals to improve early detection and personalized care.
The Solution
This technology will help doctors detect prostate cancer more precisely by counting copies of a genetic sequence known as LINE-1. These sequences often appear in larger numbers as cancer progresses. By measuring them, doctors can better understand how aggressive the cancer is and customize treatments to the patient's needs.
The Opportunity
This technology could be used in the clinical diagnostics and precision oncology industry, particularly by genetic testing companies, clinical laboratories, and oncology care providers. It would enable more accurate risk assessment, early detection, and prognosis evaluation for prostate cancer through analysis of LINE-1 activity. Additionally, it could support personalized treatment planning and monitoring of disease progression. Beyond clinical use, biopharma companies developing targeted therapies may also leverage this tool in research and clinical trials to better understand tumor dynamics and treatment response.
